Company intelligence / Profile preview
Fair Therapeutics
Utrecht, Utrecht, Netherlandsfairtherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Fair Therapeutics has completed enrollment in its pivotal Phase IIb CHOICES trial evaluating Diponecaftor, a novel CFTR triple modulator therapy, in adults with ultra-rare cystic fibrosis variants. The trial uses an organoid-based diagnostic to pre-select patients most likely to benefit from the therapy. Results are expected mid-2025.
- Therapeutic areas
- Rare Diseases
- Modalities
- Small molecules (CFTR modulators)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
HIT-CF consortium participation for clinical trials
Beyond the preview
Go deeper on Fair Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fair Therapeutics.